Biopharma | January 11, 2026
InflaRx shifts focus to lead drug, cuts costs by 30% to extend cash runway
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
InflaRx is streamlining operations and largely discontinuing non-essential activities outside izicopan’s development
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
Growing patent filings and tier-2 innovators reflect expanding national research base
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
Netherlands site will bring 500 manufacturing and 1,500 construction jobs while further strengthening Lilly's global supply chain
Dr. Jindal reflects on bridging accessibility gaps between urban and rural regions, the ethical and emotional aspects of family building, and how initiatives like adoption facilitation centers align with his lifelong mission to help couples realize the dream of parenthood
The collaboration is expected to facilitate access to world-class treatments and specialised care for Iraqi personnel
The new Houston site, Lilly's eighth U.S. manufacturing facility announced since 2020, will focus on domestic production of small molecule synthetic medicines
This marks the first of four new U.S. manufacturing sites that Lilly plans to announce this year
Minister releases five breakthrough veterinary technologies to strengthen diagnostics and combat antimicrobial resistance
Subscribe To Our Newsletter & Stay Updated
